Site Search
Google Search
search button
Breaking News: Phil Mickelson 'Stuns' At U.S. Open--And Not In A Good Way     - | -     DC Politicians Tying Themselves To Opioid Legislation     - | -     At Least 17 Killed After Tear Gas In Nightclub     - | -     Despite Ceasefire, Car Bomb Claims 26 Lives In Afghanistan     - | -     Video Referee Used For First Time At World Cup     - | -     Arab Alliance Close to Capturing Hodeidah Airport     - | -     Second Deputy Dies After She Was Shot During Fight With Prisoner     - | -     GOP Congressman Invokes 'The Deep State'
CRISPR Study Sends Biotech Stocks Tumbling
Get Business & Technology Alerts

viewsViews 532
10 Jan 2018 06:09 AM EST

On Monday, a new paper had identified a possible barrier to using the revolutionary gene-editing tool CRISPR in humans. The news sent the stocks of all three major CRISPR biotech firms tumbling in premarket trading. They declined by as much as 11.9 percent.
In recent years, CRISPR has been credited with the potential power to correct any number of devastating diseases. Researchers have used it to cure mice of deadly genetic conditions like hemophilia B, Lou Gehrig’s disease, and Huntington’s disease. In the U.S., the first human CRISPR trials are slated to begin this year.

Post Your Comment
Excellent Very Good Good Fair Poor



Recently Posted Comments
FREE
AllMediaNY AllMediaNY AllMedaiNY